2026.06.02
Research and Development of Next-Generation CAR-T Cell Therapy for Malignant Brain Tumor (Glioblastoma) Selected by AMED for Physician-Initiated Clinical Trials: An Academic-Industrial Collaboration Project by Kyushu University, Yamaguchi University, and Noile-Immune Biotech
A joint proposal by Yamaguchi University, Kyushu University Hospital, and Noile-Immune Biotech Inc. has been selected for “Seeds F” of the FY2026 Academic Research Program (Bridge Research Program) by the Japan Agency for Medical Research and Development (AMED).
In this project, Professor Koji Yoshimoto of Kyushu University (Principal Investigator) and Professor Koji Tamada of Yamaguchi University will collaborate to establish a novel treatment for glioblastoma, a highly intractable malignant brain tumor, using cutting-edge “next-generation CAR-T cells.” By incorporating a Japan-originated immune-enhancement technology designed to overcome the immunosuppressive environment of solid tumors, we will advance research and development toward launching a world-first (first-in-human) physician-initiated Phase I clinical trial.
- Division of Advanced Cell Therapy
- Koji Tamada（Immunology）
- ＜Research Inquiries＞
- Graduate School of Medicine, Yamaguchi University
- 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan
- E-mail：immunol@ ( followed by yamaguchi-u.ac.jp)
- ＜Regarding public relations＞
- Yamaguchi University Research Institute for Cell Design Medical Science (Life Science Support Section, Academic Research Division)
- TEL: 0836-85-3065
- E-mail: sh088@ ( followed by yamaguchi-u.ac.jp)